Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Uterine Fibroids: 10 Years’ Outcomes From the Randomized EMMY Trial

Authors:
  • ABAnnefleur M. de Bruijn
    Annefleur M. de Bruijn
  • WAWillem M. Ankum
    Willem M. Ankum
  • JRJim A. Reekers
    Jim A. Reekers
  • EBErwin Birnie
    Erwin Birnie
  • SKSanne M. van der Kooij
    Sanne M. van der Kooij
  • NVNicole A. Volkers
    Nicole A. Volkers
  • WHWouter J. K. Hehenkamp
    Wouter J. K. Hehenkamp

Abstract
(Abstracted from Am J Obst Gynecol 2016; DOI: 10.1016/j.ajog.2016.06.051) Since uterine artery embolization (UAE) was first described in 1995 as an alternative to hysterectomy for the treatment of symptomatic uterine fibroids, a large number of studies including several randomized controlled trials have established UAE as a valuable treatment. The randomized EMMY (EMbolization versus hysterectoMY) trial reported outcomes for clinical outcomes, efficacy, health-related quality of life (HRQOL), and cost-effectiveness after 1, 2, and 5 years of follow-up.